Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Oral Oncol ; 63: 23-29, 2016 12.
Article in English | MEDLINE | ID: mdl-27938996

ABSTRACT

OBJECTIVES: The incidence of human papillomavirus (HPV) positive oral squamous cell carcinoma (OSCC) continues to increase over time, challenging healthcare providers to address their patients' HPV-related concerns. MATERIALS AND METHODS: This prospective study assessed health literacy, HPV knowledge, utilization and trust in information sources among patients with incident HPV-positive or HPV-negative OSCC diagnosed at the Ohio State University from 2011 to 2015. Health literacy was assessed with a standardized scale. Additional questions evaluated HPV knowledge (including transmission, prevalence, health consequences and treatment), the frequency and type of information sources sought, and trust in those sources. RESULTS: Surveys were collected from 372 OSCC cases (HPV-positive, n=188; HPV-negative, n=184). Despite high mean health literacy scores, only 45.2% of HPV-related knowledge questions were answered correctly. HPV was known to be a sexually transmitted infection and a cause of cervical and anal cancer by 66.0%, 56.5% and 15.2%, respectively. In all domains, cases with HPV-positive OSCC were significantly more informed than HPV-negative cases (for all, p<0.01). Only 52.7% and 56.2% of patients with HPV-positive OSCC felt they knew enough to be comfortable discussing HPV with their doctor or sexual partner, respectively. The most frequently used information source was the internet (80.9%), which ranked 8th in trust of 15 possible sources. Although most (95.5%) patients trusted information from their doctors, only 37.9% used doctors as an information source. CONCLUSIONS: Doctors are a highly trusted, but infrequent utilized, information source and should facilitate patient access to high-quality HPV information sources.


Subject(s)
Alphapapillomavirus/isolation & purification , Carcinoma, Squamous Cell/virology , Knowledge , Mouth Neoplasms/virology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Physician-Patient Relations , Young Adult
2.
J Dent Res ; 92(2): 114-21, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23128109

ABSTRACT

An understanding of the process by which tumor cells destroy the basement membrane of the surface epithelium, invade, and metastasize is essential to the development of novel treatment of head and neck squamous cell carcinoma (HNSCC). In recent years, there has been increased interest in the role of epithelial-mesenchymal transition (EMT) in invasion. EMT is a process that describes the development of motile, mesenchymal-like cells from non-motile parent epithelial cells. There are 3 known types of EMT that mediate development, wound healing, and carcinogenesis. This review summarizes studies of known EMT biomarkers in the context of HNSCC progression. The biomarkers discussed come from a wide range of proteins, including cell-surface proteins (E-cadherin, N-cadherin, and Integrins), cytoskeletal proteins (α-Smooth Muscle Actin, Vimentin, and ß-catenin), extracellular matrix proteins (Collagens, Fibronectin, and Laminin), and transcription factors (SNAIL1, SNAIL2, TWIST, and LEF-1). Overall, the findings of these studies suggest that EMT mediates HNSCC progression. The mechanistic role of the EMT markers that have been associated with HNSCC should be more clearly defined if new anti-HNSCC therapies to block EMT progression are to be developed.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/pathology , Epithelial-Mesenchymal Transition/physiology , Neoplasm Invasiveness/pathology , Basement Membrane/pathology , Cell Adhesion/physiology , Cell Movement/physiology , Epithelial Cells/pathology , Head and Neck Neoplasms/pathology , Humans , Mesoderm/pathology
3.
Oncogene ; 32(42): 5026-37, 2013 Oct 17.
Article in English | MEDLINE | ID: mdl-23160375

ABSTRACT

Despite the dismal prognosis for patients with squamous cell carcinoma of the head and neck (SCCHN), there have been no novel treatments in over 40 years. Identification of novel tumor antigens in SCCHN will facilitate the identification of potential novel treatment targets. Tumor antigens are proteins selectively expressed by tumor cells and recognized by the host immune system. Phage-displayed tumor antigens were enriched by biopanning with normal and then SCCHN-specific serum. Ninety-six phage clones were sequenced for identification, and 21 clones were validated using Luminex. One of these proteins, L23, a novel tumor antigen in SCCHN, was validated as an oncogene. L23 is upregulated in SCCHN compared with normal keratinocytes. Knockdown of L23 inhibited proliferation, invasion and cell survival. Overexpression of L23 had the reverse effect. Overexpression of L23 in non malignant cells led to transformation. Injection of SCCHN cells with knockdown of L23 in mice, induced tumors that were significantly smaller than control tumors. In conclusion, the immunomic screen yielded a panel of antigens specific to SCCHN; one of these proteins, L23, is a novel oncogene in SCCHN.


Subject(s)
Antigens, Neoplasm/genetics , Autoantibodies/immunology , Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/immunology , Head and Neck Neoplasms/immunology , Ribosomal Proteins/genetics , Animals , Apoptosis/genetics , Biomarkers, Tumor/analysis , Biomarkers, Tumor/immunology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Case-Control Studies , Cell Line, Tumor , Cell Proliferation , Cell Surface Display Techniques , Gene Expression Regulation, Neoplastic , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/pathology , Humans , Keratinocytes/immunology , Mice , Mice, Nude , NIH 3T3 Cells , Oncogenes , Reference Values , Reproducibility of Results , Ribosomal Proteins/immunology , Squamous Cell Carcinoma of Head and Neck
4.
Oncogene ; 30(42): 4339-49, 2011 Oct 20.
Article in English | MEDLINE | ID: mdl-21532618

ABSTRACT

Rap1GAP is a critical tumor suppressor gene that is downregulated in multiple aggressive cancers, such as head and neck squamous cell carcinoma, melanoma and pancreatic cancer. However, the mechanistic basis of rap1GAP downregulation in cancers is poorly understood. By employing an integrative approach, we demonstrate polycomb-mediated repression of rap1GAP that involves Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase in head and neck cancers. We further demonstrate that the loss of miR-101 expression correlates with EZH2 upregulation, and the concomitant downregulation of rap1GAP in head and neck cancers. EZH2 represses rap1GAP by facilitating the trimethylation of histone 3 at lysine 27, a mark of gene repression, and also hypermethylation of rap1GAP promoter. These results provide a conceptual framework involving a microRNA-oncogene-tumor suppressor axis to understand head and neck cancer progression.


Subject(s)
Carcinoma, Squamous Cell/metabolism , DNA-Binding Proteins/metabolism , GTPase-Activating Proteins/metabolism , Gene Silencing , Head and Neck Neoplasms/metabolism , MicroRNAs/metabolism , Transcription Factors/metabolism , Carcinoma, Squamous Cell/genetics , Cell Line, Tumor , DNA Methylation , Enhancer of Zeste Homolog 2 Protein , GTPase-Activating Proteins/genetics , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor , Head and Neck Neoplasms/genetics , Histone Methyltransferases , Histone-Lysine N-Methyltransferase/metabolism , Histones/metabolism , Humans , Lysine/metabolism , Polycomb Repressive Complex 2 , Promoter Regions, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...